NCT03740919

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 751 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 1 Year – 17 Years
• Healthy volunteers: Not accepted

Summary

The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).

Conditions

• Type 1 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	LY900014	Administered SC
DRUG	Insulin Lispro	Administered SC
DRUG	Insulin Glargine	Administered SC
DRUG	Insulin Degludec	Administered SC

Timeline

• Start date: 2019-04-07
• Primary completion: 2021-07-02
• Completion: 2021-07-02
• First posted: 2018-11-14
• Last updated: 2022-01-24
• Results posted: 2022-01-24

Locations

111 sites across 18 countries: United States, Austria, Brazil, China, Czechia, Denmark, France, Germany, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russia, Spain, Ukraine, United Kingdom

Regulatory

• FDA-regulated drug study